March is National Kidney Month – a time to raise awareness and learn more about kidney health and kidney disease. Earlier in 2025, the U.S. Food and Drug Administration (FDA) approved Ozempic ...

Kerendia was originally approved in July 2021 to reduce cardiovascular and kidney complications in patients with chronic ...

Novo Nordisk is expanding the reach of semaglutide through new indications, seeking label expansions for Wegovy in cardiovascular disease and Ozempic in T2D patients with chronic kidney disease.

Novo Nordisk NVO announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending that Ozempic’s (once-weekly ...

Most individuals with chronic kidney disease (CKD) are unaware of their disease, according to a KDIGO controversies conference on CKD prevention.

Novo Nordisk's Ozempic was first, but it was used off-label as a weight-loss drug, and had only initially been approved as a diabetes treatment and kidney disease treatment. A person checking ...

Novo Nordisk (NVO) stock in focus as oral Wegovy is accepted for FDA review for chronic weight management. Read more here.

Novo Nordisk is continuing to monitor trial participants to see how their liver disease progresses. The company anticipates new data in 2029. Nina Agrawal contributed reporting.